Shigella resistant to Cipro ,Azithromycin on the rise

Published On 2018-06-12 13:45 GMT   |   Update On 2024-11-05 06:28 GMT

Shigella isolates with reduced susceptibility to the fluoroquinolone ciprofloxacin continue to increase, the CDC warned on Friday. Additionally, the agency is now seeing a rise in isolates resistant to the macrolide azithromycin.


Preliminary data from 2016 show that 8% of tested isolates had reduced ciprofloxacin susceptibility, and 10% had reduced azithromycin susceptibility. In 2017, the proportions were 17% and 22%, respectively.


Shigellosis usually resolves without treatment within 5 to 7 days. When antibiotic therapy is needed, clinicians should carefully monitor patients, the CDC advises. If a suspected fluoroquinolone or azithromycin treatment failure occurs, providers should:




  • Consider reaching out to an infectious disease specialist to discuss other treatment options

  • Obtain a stool specimen for additional antimicrobial susceptibility testing

  • Report the treatment failure and send an isolate to the state health department


CDC is particularly concerned about people who are at high risk for multidrug-resistant Shigella infections and are more likely to require antibiotic treatment, such as men who have sex with men, patients who are homeless, and immunocompromised patients. These patients often have a more severe disease, prolonged shedding, and recurrent infections.


Shigellosis is a type of food poisoning caused by infection with the Shigella species. It is a major public health problem in developing countries where sanitation is poor. Shigellosis is spread by means of fecal-oral transmission.


Tags:    
Article Source : With inputs from NEJM Journal Watch

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News